Corcept Therapeutics (CORT) Q2 2025 Earnings Call July 31, 2025 05:00 PM ET Speaker0Thank you for standing by, and welcome to Corcept Therapeutics Second Quarter twenty twenty five Earnings Conference Call. At this time, participants are in a listen only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. To remove yourself from the queue, you may press 11 again.I would now like to hand the call ...

公司表现 - Madrigal Pharmaceuticals旗下药物Rezdiffra获得FDA批准用于治疗非肝硬化非酒精性脂肪性肝炎成人患者 销售表现良好 [2] 行业分析服务 - Biotech Analysis Central提供针对生物制药公司的深度分析服务 包含600多篇生物科技投资文章库 [2] - 该服务提供10多只中小盘股票的投资组合模型 每只股票均有详细分析 [2] - 订阅价格为每月49美元 年度订阅可享受335%折扣 年费399美元 [1]

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainmentEAST HANOVER, N.J., July 31, ...

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (F ...

Corporate Presentation August 2025 Disclaimer This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed", the "Company", "we", "our" or "us) solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities. Any trademarks included herein are the property of the owner ...

证券代码： 603811 证券简称： 诚意药业 公告编号：2025-039 浙江诚意药业股份有限公司关于帕拉米韦注射液获得药品注册证书的公告 浙江诚意药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的帕拉米韦注射液《药品注册证书》，现将具体情况公告如下： 1、药品名称：帕拉米韦注射液 2、剂型：注射剂 3、规格：15ml：0.15g（按C??H??N?O?计） 4、证书编号：2025S02423 5、药品注册标准编号：YBH18452025 6、申请事项：药品注册(境内生产) 7、注册分类：化学药品3类 8、药品有效期：18个月 9、药品批准文号：国药准字H20255068 10、药品批准文号有效期：至2030年07月29日 11、生产企业名称：浙江诚意药业股份有限公司 12、生产企业地址：浙江省温州市洞头区化工路118号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、概况 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-050 登录新浪财经APP 搜索【信披】查看更多考评等级 二、药品其他相关情况 美沙拉秦是一种非甾体抗炎药，可以抑制引起炎症的前列腺素的合成和炎性介质白三烯的形成，从而对 肠黏膜的炎症起显著抑制作用。美沙拉秦肠溶片口服后在肠道释放美沙拉秦，适用于溃疡性结肠炎急性 发作期的治疗和防止复发的维持治疗，以及克罗恩病急性发作期的治疗，原研为德国福克制药股份有限 公司。截至本公告日，除进口产品及公司外，国内有4家企业持有该产品同规格药品批文，另有3家持有 其他规格药品批文。 三、对公司的影响及风险提示 公司美沙拉秦肠溶片获得《药品注册证书》，将进一步丰富公司产品管线，提升公司市场竞争力。由于 药品的生产和销售可能受到政策和市场等因素影响，仍具有一定的不确定性。敬请广大投资者谨慎决 策，注意投资风险。 特此公告。 合肥立方制药股份有限公司 关于取得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）收到国家药品监督管理局核准签发 ...

Key Takeaways TEVA beat Q2 earnings estimates with $0.66 per share, though revenues of $4.18B missed expectations.Branded drugs Ajovy, Austedo, and Uzedy drove U.S. sales, offsetting declines in generics and Copaxone.TEVA reaffirmed 2025 revenue guidance and raised sales outlook for Ajovy, Austedo, and Uzedy.Teva Pharmaceutical Industries (TEVA) reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the Zacks Consensus Estimate of 63 cents. Adjusted earnings rose 8% year over year, ...

Key Takeaways AbbVie posted Q2 EPS of $2.97 on $15.42 billion in revenue, beating estimates and prior company guidance.Strong sales of Rinvoq, Skyrizi, Vraylar and newer drugs offset Humira and Imbruvica declines.ABBV raised full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.AbbVie Inc. (ABBV) reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ear ...

Key Takeaways BMY posted Q2 EPS of $1.46 vs. $1.07 estimate, with revenues rising 1% to $12.2B, beating forecasts.Growth Portfolio sales rose 18% to $6.6B, led by Opdivo, Breyanzi, Reblozyl and Camzyos.BMY raised 2025 revenue guidance but cut EPS outlook due to IPRD charges from the BNTX partnership.Bristol-Myers Squibb Company ((BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably beat the Zacks Consensus Estimate of $1.07. In the year-ago quarter, BMY posted adju ...